Search｜Photos & Images & Videos｜KYODO NEWS IMAGES INC

Japan gov't panel approves 2 iPS-derived drugs

University of Osaka professor Yoshiki Sawa holds a press conference in Osaka on Feb. 19, 2026, after Japan's health ministry panel approved the commercialization of two regenerative medicine products prepared from iPS cells, the first of their kind in the world. One of the two drugs, ReHeart, heart muscle sheets derived from human iPS cells, was developed by a startup originating from Sawa's team at the university.

E

Japan gov't panel approves 2 iPS-derived drugs

University of Osaka professor Yoshiki Sawa holds a press conference in Osaka on Feb. 19, 2026, after Japan's health ministry panel approved the commercialization of two regenerative medicine products prepared from iPS cells, the first of their kind in the world. One of the two drugs, ReHeart, heart muscle sheets derived from human iPS cells, was developed by a startup originating from Sawa's team at the university.

E

Japan gov't panel approves 2 iPS-derived drugs

University of Osaka professor Yoshiki Sawa holds a press conference in Osaka on Feb. 19, 2026, after Japan's health ministry panel approved the commercialization of two regenerative medicine products prepared from iPS cells, the first of their kind in the world. One of the two drugs, ReHeart, heart muscle sheets derived from human iPS cells, was developed by a startup originating from Sawa's team at the university.